BidaskClub upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a buy rating to a strong-buy rating in a research note released on Thursday.

A number of other brokerages have also recently weighed in on ARWR. B. Riley began coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a neutral rating and a $3.00 price target on the stock. ValuEngine raised shares of Arrowhead Pharmaceuticals from a strong sell rating to a sell rating in a research report on Monday, October 2nd. Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price target on the stock in a research report on Monday, November 27th. Finally, Cantor Fitzgerald set a $2.00 price target on shares of Arrowhead Pharmaceuticals and gave the company a hold rating in a research report on Tuesday, December 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $3.13.

Shares of Arrowhead Pharmaceuticals (ARWR) traded up $0.57 during mid-day trading on Thursday, reaching $6.29. 4,717,371 shares of the company’s stock were exchanged, compared to its average volume of 2,140,000. The firm has a market capitalization of $470.67, a PE ratio of -13.38 and a beta of 1.79. The company has a current ratio of 3.63, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 1 year low of $1.42 and a 1 year high of $6.40.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative net margin of 109.46% and a negative return on equity of 38.10%. research analysts anticipate that Arrowhead Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

In other news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction on Monday, January 1st. The shares were sold at an average price of $3.69, for a total transaction of $73,800.00. Following the transaction, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.57% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 1,177.7% during the fourth quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 66,055 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 8.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock worth $686,000 after purchasing an additional 15,132 shares in the last quarter. Allianz Asset Management GmbH acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $1,958,000. Dimensional Fund Advisors LP lifted its position in shares of Arrowhead Pharmaceuticals by 252.2% during the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 31,765 shares in the last quarter. Finally, ING Groep NV acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $3,500,000. 20.05% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals (ARWR) Lifted to Strong-Buy at BidaskClub” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/01/19/arrowhead-pharmaceuticals-arwr-lifted-to-strong-buy-at-bidaskclub.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.